Thursday, October 22, 2020
Home Latest Pharma-News RPS calls for action to fight counterfeit medicines

RPS calls for action to fight counterfeit medicines

October 13, 2020: The Royal Pharmaceutical Society of Great Britain (RPS) has called on the UK government to take immediate action to fight counterfeit medicines from entering the country following the UK’s exit from the European Union.

The RPS, in a letter addressed to Health Secretary Matt Hancock, emphasised the need for rigorous plans to be put in place to maintain formal links with the EU. This will help to authenticate the legitimacy of medicines that move between the EU and the UK.

- Advertisement -

Under current plans, the UK will cease to benefit from the provisions of the Falsified Medicines Directive (FMD). This ensures that medicines in the EU are legitimate, safe and high-quality.

The RPS has presented concerns that this could leave the UK vulnerable to a swarm of counterfeit medicine entering the supply chain, which could impact patient care in the UK and across the EU.

“In our letter to the Government we have emphasised that establishing technical agreements with the EU is now more critical than ever in our fight against counterfeit medicines. We have made it clear that the ideal way forward is for continuity of the provisions of the Falsified Medicines Directive, enabling ongoing connectivity between the UK and Europe,” said Sandra Gidley, president of the RPS.

“Not only will this help to provide assurances to patients about the safety of their medicines but it will also ensure the UK can continue to benefit from the significant investment made by the NHS, pharmacy organisations and individual pharmacy owners in the infrastructure for FMD,” she added.
https://www.rpharms.com/about-us/news/details/rps-calls-for-action-to-fight-counterfeit-medicines

LEAVE A REPLY

Please enter your comment!
Please enter your name here

sixteen − 4 =

Most Popular

AZ’s Tagrisso scores priority review from FDA with EGFR-mutated lung cancer

October 20, 2020: "AstraZeneca’s Tagrisso (osimertinib) has received acceptance for its supplemental New Drug Application (sNDA) and has also been granted Priority Review in...

Forxiga recommended for approval in the EU by CHMP for heart failure

October 19, 2020: "AstraZeneca’s Forxiga (dapagliflozin) has been recommended for an indication extension of its marketing authorisation in the European Union (EU) for the...

AstraZeneca advances leadership in renal disease at ASN Kidney Week 2020 Reimagined

October 20, 2020: AstraZeneca will present 84 abstracts, including 12 oral presentations and three late-breaking abstracts, across its industry-leading renal portfolio which...

AbbVie’s VENCLEXTA® Receives FDA Approval for Acute Myeloid Leukemia

October 16, 2020: "AbbVie announced that the U.S. Food and Drug Administration (FDA) has provided full approval to VENCLEXTA® (venetoclax) in combination...